Achieve Life Sciences (ACHV) Projected to Announce Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Achieve Life Sciences to announce earnings of ($0.18) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.11. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV opened at $6.32 on Tuesday. Achieve Life Sciences has a 1 year low of $2.37 and a 1 year high of $7.11. The business has a fifty day simple moving average of $5.81 and a 200 day simple moving average of $4.85. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87. The firm has a market cap of $648.81 million, a price-to-earnings ratio of -5.64 and a beta of 2.24.

Institutional Trading of Achieve Life Sciences

Several hedge funds have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the first quarter valued at approximately $32,000. Magnolia Capital Advisors LLC acquired a new position in Achieve Life Sciences during the 4th quarter valued at $64,000. HRT Financial LP acquired a new position in Achieve Life Sciences during the 4th quarter valued at $93,000. Charles Schwab Investment Management Inc. bought a new stake in Achieve Life Sciences in the 4th quarter valued at $99,000. Finally, Jump Financial LLC bought a new stake in Achieve Life Sciences in the 4th quarter valued at $104,000. Institutional investors own 33.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ACHV shares. UBS Group reaffirmed a “buy” rating on shares of Achieve Life Sciences in a research note on Tuesday, June 23rd. Wall Street Zen raised shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Raymond James Financial initiated coverage on Achieve Life Sciences in a report on Friday, June 26th. They set a “strong-buy” rating and a $20.00 target price on the stock. Weiss Ratings upgraded Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the company a “buy” rating in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $16.00.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.